TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

3 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Dementia / Alzheimer's

    Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

    Testing a treatment with IL-2 and semaglutide in people with Alzheimer's

    📍 Houston Methodist Research Institute · Houston, TX · Get directions →

    Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.

    ✓ Study care freePhase 1Ages 50–86Learn more →
  • Crohn's / ulcerative colitis (IBD)

    Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

    Testing diet plus an injectable medicine to treat mild Crohn’s in people with higher BMI

    📍 University of Miami · Miami, FL · Get directions →

    The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) for Crohn's disease patients with mild disease who are on stable doses of biologic medication (infliximab or adalimumab) and who have a body mass index (BMI) of at least 27.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • DepressionAnxiety

    Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation

    Testing whether a brain drug affects decision-making in depression and anxiety

    📍 Mclean Hospital · Belmont, MA · Get directions →

    The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).

    ✓ Study care freePhase 2Ages 18–45Learn more →